Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

Phase 2

Completed

Conditions: Recurrent Bladder Urothelial Carcinoma
Recurrent Urethral Urothelial Carcinoma
Recurrent Renal Pelvis Urothelial Carcinoma
Stage 0a Ureter Cancer AJCC v8
Stage II Ureter Cancer AJCC v8
Stage III Renal Pelvis Cancer AJCC v8
Recurrent Ureter Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0a Renal Pelvis Cancer AJCC v8
Stage 0a Urethral Cancer AJCC v8

Interventions: Drug: Erlotinib Hydrochloride

First Posted Date: 2008-09-09

Last Posted Date: 2020-09-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT00749892

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Attitudes and Beliefs and the Steps of HIV Care

Completed

Conditions: Human Immunodeficiency Virus Infections

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-09-09

Last Posted Date: 2013-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT00749840

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States

Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)

Completed

Conditions: Brain Tumor

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-09-09

Last Posted Date: 2016-01-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 115

Registration Number: NCT00748774

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

Phase 2

Completed

Conditions: Chemotherapeutic Agent Toxicity
Diarrhea
Colorectal Cancer

Interventions: Drug: calcium aluminosilicate anti-diarrheal
Other: placebo

First Posted Date: 2008-09-08

Last Posted Date: 2020-12-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00748215

Locations: 🇺🇸
CCOP - Columbia River Oncology Program, Portland, Oregon, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: ZD6474 (ZACTIMA)
Radiation: Radiation Therapy

First Posted Date: 2008-09-03

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00745732

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer

Phase 2

Terminated

Conditions: Recurrent Rectal Carcinoma
Stage IIA Rectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIB Rectal Cancer AJCC v7
Stage IIC Rectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7
Rectal Mucinous Adenocarcinoma
Rectal Signet Ring Cell Adenocarcinoma

Interventions: Drug: Capecitabine
Dietary Supplement: Curcumin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Placebo
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2008-09-03

Last Posted Date: 2023-09-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00745134

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Tarceva

First Posted Date: 2008-08-21

Last Posted Date: 2012-03-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00739063

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire
Other: Phone Calls

First Posted Date: 2008-08-21

Last Posted Date: 2020-01-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 102

Registration Number: NCT00738998

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Relaxation and Heart Rate Variability

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Guided Relaxation

First Posted Date: 2008-08-15

Last Posted Date: 2011-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00735618

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1

Terminated

Conditions: Glioblastoma
Gliosarcoma

Interventions: Drug: Temozolomide
Radiation: Radiation
Drug: Sorafenib

First Posted Date: 2008-08-14

Last Posted Date: 2018-11-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00734526

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy